These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

236 related items for PubMed ID: 29482913

  • 1. Single onabotulinumtoxinA 200U dose improved clinical symptoms but not urothelial dysfunction in neurogenic detrusor overactivity due to spinal cord injury.
    Chen SF, Jiang YH, Kuo HC.
    J Formos Med Assoc; 2019 Jan; 118(1 Pt 1):125-133. PubMed ID: 29482913
    [Abstract] [Full Text] [Related]

  • 2. Clinical Efficacy and Changes of Urothelial Dysfunction after Repeated Detrusor Botulinum Toxin A Injections in Chronic Spinal Cord-Injured Bladder.
    Chen SF, Chang CH, Kuo HC.
    Toxins (Basel); 2016 May 30; 8(6):. PubMed ID: 27249005
    [Abstract] [Full Text] [Related]

  • 3. Effect of detrusor botulinum toxin a injection on urothelial dysfunction in patients with chronic spinal cord injury: a clinical and immunohistochemistry study before and after treatment.
    Chen SF, Chang CH, Kuo HC.
    Spinal Cord; 2016 Oct 30; 54(10):889-894. PubMed ID: 26832760
    [Abstract] [Full Text] [Related]

  • 4. The therapeutic effects of repeated detrusor injections between 200 or 300 units of onabotulinumtoxinA in chronic spinal cord injured patients.
    Chen YC, Kuo HC.
    Neurourol Urodyn; 2014 Jan 30; 33(1):129-34. PubMed ID: 23494629
    [Abstract] [Full Text] [Related]

  • 5. Therapeutic outcome and patient adherence to repeated onabotulinumtoxinA detrusor injections in chronic spinal cord-injured patients and neurogenic detrusor overactivity.
    Chen SF, Kuo HC.
    J Formos Med Assoc; 2015 Jul 30; 114(7):583-9. PubMed ID: 24262922
    [Abstract] [Full Text] [Related]

  • 6. OnabotulinumtoxinA improves urodynamic outcomes in patients with neurogenic detrusor overactivity.
    Rovner E, Dmochowski R, Chapple C, Thompson C, Lam W, Haag-Molkenteller C.
    Neurourol Urodyn; 2013 Nov 30; 32(8):1109-15. PubMed ID: 23389824
    [Abstract] [Full Text] [Related]

  • 7. Urothelial Dysfunction and Chronic Inflammation in Diabetic Patients with Overactive Bladder.
    Wang CC, Kuo HC.
    Low Urin Tract Symptoms; 2017 Sep 30; 9(3):151-156. PubMed ID: 27018971
    [Abstract] [Full Text] [Related]

  • 8. OnabotulinumtoxinA is effective in patients with urinary incontinence due to neurogenic detrusor overactivity [corrected] regardless of concomitant anticholinergic use or neurologic etiology.
    Ginsberg D, Cruz F, Herschorn S, Gousse A, Keppenne V, Aliotta P, Sievert KD, Brin MF, Jenkins B, Thompson C, Lam W, Heesakkers J, Haag-Molkenteller C.
    Adv Ther; 2013 Sep 30; 30(9):819-33. PubMed ID: 24072665
    [Abstract] [Full Text] [Related]

  • 9. Botulinum toxin A detrusor injections reduce postsynaptic muscular M2, M3, P2X2, and P2X3 receptors in children and adolescents who have neurogenic detrusor overactivity: a single-blind study.
    Schulte-Baukloh H, Priefert J, Knispel HH, Lawrence GW, Miller K, Neuhaus J.
    Urology; 2013 May 30; 81(5):1052-7. PubMed ID: 23419459
    [Abstract] [Full Text] [Related]

  • 10. Botulinum toxin A injection for the treatment of neurogenic detrusor overactivity secondary to spinal cord injury: multi-institutional experience in Japan.
    Sengoku A, Okamura K, Kimoto Y, Ogawa T, Namima T, Yamanishi T, Yokoyama T, Akino H, Maeda Y.
    Int J Urol; 2015 Mar 30; 22(3):306-9. PubMed ID: 25403926
    [Abstract] [Full Text] [Related]

  • 11. More Than 15 Years of Experience with Intradetrusor OnabotulinumtoxinA Injections for Treating Refractory Neurogenic Detrusor Overactivity: Lessons to Be Learned.
    Leitner L, Guggenbühl-Roy S, Knüpfer SC, Walter M, Schneider MP, Tornic J, Sammer U, Mehnert U, Kessler TM.
    Eur Urol; 2016 Sep 30; 70(3):522-8. PubMed ID: 27106070
    [Abstract] [Full Text] [Related]

  • 12. Meta-analysis of botulinum toxin A detrusor injections in the treatment of neurogenic detrusor overactivity after spinal cord injury.
    Mehta S, Hill D, McIntyre A, Foley N, Hsieh J, Ethans K, Teasell RW, Loh E, Welk B, Wolfe D.
    Arch Phys Med Rehabil; 2013 Aug 30; 94(8):1473-81. PubMed ID: 23632286
    [Abstract] [Full Text] [Related]

  • 13. Impairment of sensory afferents by intrathecal administration of botulinum toxin A improves neurogenic detrusor overactivity in chronic spinal cord injured rats.
    Coelho A, Oliveira R, Cruz F, Cruz CD.
    Exp Neurol; 2016 Nov 30; 285(Pt B):159-166. PubMed ID: 27235935
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial.
    Cruz F, Herschorn S, Aliotta P, Brin M, Thompson C, Lam W, Daniell G, Heesakkers J, Haag-Molkenteller C.
    Eur Urol; 2011 Oct 30; 60(4):742-50. PubMed ID: 21798658
    [Abstract] [Full Text] [Related]

  • 15. Urothelial dysfunction and chronic inflammation in patients with spinal cord injuries at different levels and correlation with urodynamic findings.
    Jiang YH, Liu HT, Kuo HC.
    Neurourol Urodyn; 2015 Nov 30; 34(8):757-62. PubMed ID: 25065363
    [Abstract] [Full Text] [Related]

  • 16. Treatment of neurogenic detrusor overactivity and overactive bladder with Botox (onabotulinumtoxinA): Development, insights, and impact.
    Nitti V, Haag-Molkenteller C, Kennelly M, Chancellor M, Jenkins B, Schurch B.
    Medicine (Baltimore); 2023 Jul 01; 102(S1):e32377. PubMed ID: 37499088
    [Abstract] [Full Text] [Related]

  • 17. Urothelial Barrier Deficits, Suburothelial Inflammation and Altered Sensory Protein Expression in Detrusor Underactivity.
    Jiang YH, Kuo HC.
    J Urol; 2017 Jan 01; 197(1):197-203. PubMed ID: 27436428
    [Abstract] [Full Text] [Related]

  • 18. Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity.
    Ginsberg D, Gousse A, Keppenne V, Sievert KD, Thompson C, Lam W, Brin MF, Jenkins B, Haag-Molkenteller C.
    J Urol; 2012 Jun 01; 187(6):2131-9. PubMed ID: 22503020
    [Abstract] [Full Text] [Related]

  • 19. Patient-reported goal achievement following onabotulinumtoxinA treatment in patients with neurogenic detrusor overactivity.
    Chartier-Kastler E, Rovner E, Hepp Z, Khalaf K, Ni Q, Chancellor M.
    Neurourol Urodyn; 2016 Jun 01; 35(5):595-600. PubMed ID: 25846869
    [Abstract] [Full Text] [Related]

  • 20. Therapeutic effects of detrusor botulinum toxin A injection on neurogenic detrusor overactivity in patients with different levels of spinal cord injury and types of detrusor sphincter dyssynergia.
    Chen CY, Liao CH, Kuo HC.
    Spinal Cord; 2011 May 01; 49(5):659-64. PubMed ID: 21243000
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.